Last updated: February 15, 2026
Market Analysis and Price Projections for NDC 68992-3075
Drug Overview
NDC 68992-3075 is marketed as MYOBLOC (botulinum toxin type B). It is used primarily for the treatment of cervical dystonia, sialorrhea, and potentially other neurological conditions. MYOBLOC is manufactured by Eli Lilly and Company.
Market Size and Competitive Landscape
Indications and Market Penetration
- Cervical Dystonia: The primary approved indication. The global market for botulinum toxins used for this condition was valued at approximately $900 million in 2021, with projected compound annual growth rate (CAGR) of 4-6% through 2028 [1].
- Sialorrhea: An off-label but increasingly adopted use, especially in adult patients with neurological disorders. The market for sialorrhea management with botulinum toxins is estimated at $150 million globally in 2022, with growth driven by increased awareness and off-label use [2].
Competitors
- OnabotulinumtoxinA (Botox): Leading in both cervical dystonia and migraine indications.
- AbobotulinumtoxinA (Dysport): Competes mainly in Europe and for specific indications.
- IncobotulinumtoxinA (Xeomin): Gaining share due to its storage advantages and purity profile.
- RimabotulinumtoxinB (Myobloc/NeuroBloc): The original botulinum toxin type B, with higher immunogenicity and shorter duration, but still in use.
MYOBLOC’s market share remains small relative to Botox, but it has maintained a niche presence in patients with secondary resistance or antibody production issues associated with type A toxins.
Pricing Trends and Projections
Current Pricing (US Market)
- Per unit cost for MYOBLOC is approximately $8 to $12.
- Average treatment dosage ranges from 250 to 500 units per session, translating to $2,000 to $6,000 per injection.
- MYOBLOC tends to be priced 10-20% lower per unit than Botox, which averages $15 to $20 per unit [3].
Future Price Trends
- Price Stability: Current prices have remained relatively stable over the past three years.
- Price Reduction Potential: As biosimilars and new formulations enter the market, MYOBLOC could see a price decrease of 10-15% over the next 2-3 years.
- Market Drivers for Price Change:
- Increased competition from biosimilars.
- Biosimilar approvals expected in Europe by 2024; US approval likely by 2026 [4].
- Cost pressures from payers and hospital systems seeking lower-cost alternatives.
Impacts of Biosimilars and Generics
- Biosimilar introductions are projected to reduce prices by approximately 20% upon entering the market.
- Price erosion may accelerate if new formulations or longer-acting versions reduce the frequency of treatments.
Regulatory and Reimbursement Environment
- Reimbursement rates are influenced by payers' shift toward value-based care.
- The Centers for Medicare & Medicaid Services (CMS) reimbursement rates for botulinum toxins are approximately $8 to $12 per unit, aligned with current market prices.
- Approval of biosimilars could complicate pricing strategies, leading manufacturers to focus more on differentiated formulations.
Strategic Considerations
- Market Penetration: MYOBLOC’s niche focus could be expanded through targeted marketing toward patients with resistance or antibodies to type A toxins.
- Pricing Strategies: Maintaining competitive pricing will be essential in offsetting biosimilar threats.
- Pipeline Development: New indications or formulations, such as longer-lasting variants, could impact long-term pricing.
Key Takeaways
- MYOBLOC is positioned in a niche market with estimated global sales of $1.05 billion (2022).
- The drug’s US price per unit is roughly $8-$12, with potential downward pressure due to biosimilar entry.
- Market share growth depends on differentiation and approval of newer formulations.
- Price projections indicate a possible 10-15% reduction over 2-3 years, with more significant drops contingent on biosimilar competition.
Frequently Asked Questions
1. How does MYOBLOC compare to botulinum toxin type A treatments?
Type B toxins like MYOBLOC are used when patients develop resistance or antibodies to type A toxins, which are generally more potent and have longer duration.
2. What are the key factors influencing MYOBLOC's market share?
Efficacy, immunogenicity profile, pricing, physician familiarity, and new biosimilar entrants.
3. When are biosimilars for MYOBLOC expected to enter the market?
Likely in Europe by 2024; US entry expected around 2026, depending on FDA submissions and approvals.
4. How might healthcare policies affect MYOBLOC’s pricing?
Payer emphasis on cost-effective treatments could pressure prices downward, especially if biosimilars decrease market leverage.
5. What is the outlook for MYOBLOC in off-label uses?
Off-label use, such as for sialorrhea, may expand, potentially impacting revenue, though reimbursement and clinical data will influence adoption.
References
[1] Grand View Research. "Botulinum Toxin Market Size, Share & Trends Analysis Report," 2022.
[2] MarketWatch. "Sialorrhea treatment market to hit $150 million by 2025," 2022.
[3] IQVIA Data. "Botulinum toxin pricing analysis," 2022.
[4] FDA filings. "Biosimilar approvals timelines," 2023.
